Healthcare of Ontario Pension Plan Trust Fund Sells 22,652 Shares of GRAIL, Inc. $GRAL

Healthcare of Ontario Pension Plan Trust Fund decreased its position in shares of GRAIL, Inc. (NASDAQ:GRAL) by 58.8% during the first quarter, HoldingsChannel reports. The institutional investor owned 15,843 shares of the company’s stock after selling 22,652 shares during the period. Healthcare of Ontario Pension Plan Trust Fund’s holdings in GRAIL were worth $819,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. N.E.W. Advisory Services LLC bought a new position in GRAIL in the 4th quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd purchased a new stake in GRAIL during the 4th quarter valued at $28,000. Elyxium Wealth LLC bought a new stake in shares of GRAIL in the 4th quarter worth $31,000. Comerica Bank lifted its holdings in shares of GRAIL by 59.2% during the third quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after purchasing an additional 173 shares in the last quarter. Finally, Fifth Third Bancorp increased its holdings in GRAIL by 15,733.3% in the 1st quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock worth $25,000 after buying an additional 472 shares in the last quarter.

GRAIL News Summary

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: GRAIL will present at the Canaccord Genuity 46th Annual Growth Conference on August 11. Management’s appearance could provide updates on commercial execution, adoption of its Galleri cancer-detection test and future growth plans. GRAIL to Present at the Canaccord Genuity 46th Annual Growth Conference
• Neutral Sentiment: GRAIL is expected to report its next quarterly results on Wednesday. The report may become the next major catalyst, particularly given the company’s continued losses and the market’s focus on revenue growth, cash usage and guidance. GRAIL Expected to Post Earnings on Wednesday
• Negative Sentiment: Multiple law firms publicized or reiterated a securities class action against GRAIL and certain executives, covering investors who purchased shares between May 13, 2025, and February 19, 2026. The firms allege federal securities-law violations connected with investor losses and are soliciting lead-plaintiff applicants.
• Negative Sentiment: The August 4, 2026 lead-plaintiff deadline is generating repeated investor alerts from Rosen, Hagens Berman, Robbins Geller, Bleichmar Fonti & Auld, and other firms. Although the allegations have not been proven, the concentration of notices can increase uncertainty around potential damages, legal expenses and management attention. Rosen Law Firm GRAIL Investor Deadline Notice

Wall Street Analysts Forecast Growth

Several research firms have issued reports on GRAL. Robert W. Baird set a $70.00 target price on shares of GRAIL in a research note on Wednesday, May 6th. Wall Street Zen upgraded shares of GRAIL from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a report on Friday, July 17th. The Goldman Sachs Group initiated coverage on shares of GRAIL in a research report on Friday, June 5th. They set a “neutral” rating and a $60.00 price objective on the stock. Finally, Mizuho lifted their target price on shares of GRAIL from $58.00 to $65.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 15th. Four analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, GRAIL presently has a consensus rating of “Hold” and a consensus target price of $67.78.

GRAIL Stock Performance

GRAL opened at $68.56 on Monday. The company’s 50 day moving average is $66.78 and its 200 day moving average is $67.33. The company has a market cap of $2.94 billion, a price-to-earnings ratio of -6.61 and a beta of 3.24. GRAIL, Inc. has a 12-month low of $29.95 and a 12-month high of $118.84.

GRAIL (NASDAQ:GRAL) last announced its earnings results on Tuesday, May 5th. The company reported ($2.29) EPS for the quarter, beating analysts’ consensus estimates of ($2.76) by $0.47. The business had revenue of $40.78 million during the quarter, compared to analysts’ expectations of $39.16 million. GRAIL had a negative net margin of 253.22% and a negative return on equity of 16.42%. As a group, analysts predict that GRAIL, Inc. will post -10.91 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Andrew John Partridge sold 1,491 shares of GRAIL stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $61.08, for a total transaction of $91,070.28. Following the transaction, the insider directly owned 163,738 shares in the company, valued at approximately $10,001,117.04. The trade was a 0.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.83% of the company’s stock.

GRAIL Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.